Gland Pharma invests $21 million in US subsidiary

Gland Pharma announced a $21 million investment in its US subsidiary, Gland Pharma USA Inc, to acquire 60% equity in newly incorporated Novelstar Pharma Inc. The acquisition is expected by October 31, 2026. The company also saw board changes, with Wenjie Zhang resigning and Xingli Wang appointed as additional director, effective October 1, 2026.